Bruker Corporation — FY2012 Form 10-K
Reporting period: Fiscal year ended December 31, 2012. The filing also reports unaudited fourth-quarter results; it is an annual report, not a standalone Q4 filing. Bruker designs and sells scientific instruments, analytical systems, and superconducting materials and devices. Its reportable segments are Scientific Instruments and Energy & Supercon Technologies.
Financial performance and position
| Metric | FY2012 | FY2011 |
|---|---|---|
| Revenue | $1,791.4 million | $1,651.7 million |
| Gross profit / margin | $831.4 million / 46.4% | $752.5 million / 45.6% |
| Operating income / margin | $156.0 million / 8.7% | $155.6 million / 9.4% |
| Net income attributable to Bruker | $77.5 million | $92.3 million |
| Diluted earnings per share | $0.46 | $0.55 |
| Cash from operating activities | $133.1 million | $87.7 million |
| Capital expenditures | $72.8 million | $61.6 million |
- Revenue grew 8.5% as reported; excluding foreign exchange and acquisitions, management reported growth of 11.9%. Currency translation reduced FY2012 revenue by about $76.8 million; acquisitions added about $19.8 million.
- Gross margin improved, while operating margin declined. Management cited higher-margin new products and technology-license revenue, offset by pricing pressure, product mix, higher expenses, and asset impairments.
- Cash and cash equivalents were $310.6 million, up from $246.0 million. Working capital was $627.9 million. Current assets of $1,309.7 million compared with current liabilities of $681.8 million.
- Total debt was $337.2 million, versus $303.1 million. The company reported $199.3 million available under revolving facilities and was in compliance with debt covenants at year-end.
- Operating cash flow was $133.1 million; investing cash outflow was $93.2 million and financing cash inflow was $34.4 million. Inventory growth was a significant working-capital use. Approximately 92.8% of cash was held by foreign subsidiaries.
Material changes and unusual items
- Scientific Instruments revenue increased 7.2% to $1,666.1 million; Energy & Supercon Technologies revenue increased 20.1% to $136.2 million. The latter segment returned to operating income of $12.8 million from a $4.1 million loss.
- Scientific Instruments operating income fell to $140.8 million from $162.8 million, with reported segment margin declining to 8.5% from 10.5%.
- FY2012 included $23.8 million of impairment charges: $1.4 million goodwill, $16.4 million definite-lived intangibles, and $6.0 million other long-lived assets. The fourth quarter included the full impairment charge.
- Other charges were $13.9 million, including $11.1 million for legal and professional costs related to the China compliance investigation and $2.0 million of factory relocation costs. Net interest and other expense increased to $17.7 million from $10.1 million; the effective tax rate rose to 43.5% from 35.4%.
- Fourth-quarter 2012 revenue was $517.3 million, operating income $39.2 million, and net income attributable to Bruker $12.8 million, compared with $475.1 million, $53.7 million, and $39.1 million, respectively, in Q4 2011.
- Year-end system backlog was $1,035.4 million, down from $1,086.5 million; the company expected to fill approximately 80% during 2013.
Outlook, risks, and contingencies
- Management said existing cash and credit facilities were expected to support operating and investing needs for at least 12 months. It anticipated approximately $55 million in 2013 capital spending, about $13 million of interest expense, and $20–$25 million of expense for facility exits and outsourcing initiatives.
- No specific revenue or earnings guidance was provided. Management noted softening demand, particularly in Europe, and weakness in global industrial and applied markets and semiconductor and data-storage metrology; the duration and impact were uncertain. Cost-control initiatives and facility closures were planned for 2013.
- The company disclosed evidence of improper payments benefiting employees or agents of government-owned enterprises in China and Hong Kong. U.S. and Hong Kong authorities were conducting inquiries, and a review of other China operations remained ongoing. Potential penalties or other outcomes could not be estimated; no provision was recorded.
- Other disclosed exposures include patent and contract lawsuits with unspecified damages, foreign-exchange and raw-material costs, reliance on limited or single-source suppliers, customer and government capital-spending levels, acquisition integration, and pension underfunding. The filing says the company cannot reasonably assess the outcome of the compliance inquiries or the cited lawsuits.
- Ernst & Young issued unqualified opinions on the financial statements and internal control over financial reporting; management also concluded disclosure controls were effective.
Important facts for investors to verify
- Progress and potential financial consequences of the FCPA/China inquiries, including whether any provision or loss estimate becomes appropriate.
- Whether the 2013 restructuring, facility exits, and outsourcing achieve expected savings without disrupting production, backlog conversion, or margins.
- Underlying demand trends and backlog conversion, especially in Europe, industrial/applied markets, and semiconductor and data-storage metrology.
- Cash availability for U.S. obligations given that most cash is held overseas, alongside debt maturities, covenant headroom, and interest costs.
- Whether CAM performance stabilizes after the impairments and whether further asset impairments or restructuring charges arise.